This study aims to develop new immunotheranostic TMs using BBN2 peptides for diagnostic imaging using positron emission tomography (PET) and UniCAR T-cell therapy to specifically target GRPR in prostate cancer. The gene discussed is GRPR; the disease is prostate carcinoma.